Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Hits New 12-Month High – Should You Buy?

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) reached a new 52-week high during trading on Thursday . The stock traded as high as $11.28 and last traded at $10.94, with a volume of 27479 shares changing hands. The stock had previously closed at $10.76.

Analyst Ratings Changes

Separately, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Fresenius SE & Co. KGaA in a research report on Monday, February 3rd.

Fresenius SE & Co. KGaA Trading Down 5.3 %

The firm has a market cap of $23.14 billion, a P/E ratio of 49.33 and a beta of 0.86. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.05 and a current ratio of 1.36. The firm has a fifty day moving average of $10.28 and a 200-day moving average of $9.49.

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) last issued its quarterly earnings data on Wednesday, February 26th. The company reported $0.18 earnings per share for the quarter. The firm had revenue of $6.01 billion during the quarter. Equities research analysts forecast that Fresenius SE & Co. KGaA will post 0.79 earnings per share for the current year.

Fresenius SE & Co. KGaA Company Profile

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.